Subtype-Specific Mutations Raise Relapse Risk in Common Childhood Leukemia
Researchers at St. Jude Children's Research Hospital have identified specific genetic mutations in B-cell acute lymphoblastic leukemia that are linked to higher relapse risks. These findings could allow doctors to tailor treatment intensity based on a patient's unique tumor profile.
Why it matters
Personalized medicine approaches like this are essential for improving survival rates in pediatric cancer patients who are resistant to standard therapies.
(MEMPHIS, Tenn. - November 02, 2026) Some cases of the most common childhood cancer, B-cell acute lymphoblastic leukemia (B-ALL), return after treatment - and genetic changes present from the start may help explain why. Scientists at St. Jude Children's Research Hospital and Seattle Children's Hospital, in collaboration with the Children's Oncology Group, found that mutations in a patient's original tumor can be associated with relapse risk, and that these changes differ by leukemia subtype. The findings, published today in Blood, could help researchers better estimate and adjust for relapse risk before treatment begins.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in